MTNB — Matinas BioPharma Holdings Inc
AMEX · Healthcare · Biotechnology
$0.20
-$0.00 (-0.30%)
Matinas BioPharma Holdings Inc (MTNB) is a biotechnology company listed on AMEX. It is led by Jerome D. Jabbour J.D., based in 1545 Route 206 South, Bedminster, NJ, United States, 07921, with about 2 employees. Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Net income was -$1.5M. MTNB currently screens at market cap $5.6M.
Use this MTNB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MTNB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MTNB SEC filings page. Lician reads the product cache first so this HTML stays unique to Matinas BioPharma Holdings Inc even when a live quote feed is slow.
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
MTNB Key Statistics
Market Cap
$5.59M
Volume
992,171
Previous Close
$0.20
Day Range
$0.20 – $0.21
EPS
-$4.98
Revenue
$0.00
Net Income
-$24.25M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
2
MTNB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.10M | $3.19M | $33.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.25M | -$22.94M | -$21.00M | $23.30M |
| EPS (Diluted) | -$4.98 | -$5.28 | -$0.10 | $0.00 |
Total Assets
$12.64M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$7.28M
Operating Cash Flow
-$15.88M
Free Cash Flow
$0.00
Matinas BioPharma Holdings Inc Company Information
- Co-Founder, Chairman, CEO, President & Interim CFO
- Jerome D. Jabbour J.D.
- Headquarters
- 1545 Route 206 South, Bedminster, NJ, United States, 07921
- Website
- www.matinasbiopharma.com
- Phone
- 908 484 8805
- IPO / Founded
- 2014-08-18
- Sector
- Healthcare
- Industry
- Biotechnology